The re-rate journey

This stock looks like it is right now right at the begining of its re-rate journey back to its previous ATH, with US market distribution deals coming soon.

And of course the long list of countries in the EU, Japan, Canada, Australia, Brazil, Saudi Arabia where it's product has been approved. I believe we are going to see more and more countries added to the list of so far only 4 EU countries or markets covered by distribution deals with Henry Schein in the weeks and months ahead.

Henry Schein as a distribution partner is definitely the top notch partner for LUMOS to work with. You couldn't ask for a better partner.


This is a 10-bag-potential stock to hold onto IMO. Current MC is simply too cheap for a medical stock with EU, JAPAN, BRAZIL, USA, AUSTRALIA, CANADA, SAUDI ARABIA,... approvals granted.